Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2015

View Archived Issues

14-3-3eta shows potential as a drug target for the treatment of arthritis

Novartis reviews pipeline progress at investor day

MicroBiome Therapeutics discloses clinical data on the antidiabetic drug NM-505

Intas launches ranibizumab biosimilar in India

Western Oncolytics closes financing round to advance cancer immunotherapy

Calithera selects oral arginase inhibitor CB-1158 as immuno-oncology clinical candidate

DBV Technologies plans phase III study of Viaskin Peanut

IBT plans clinical trials of IBP-9414 for prevention of necrotizing enterocolitis

Alcobra releases phase II data on MDX for fragile X syndrome

First-in-human study shows promising results for a novel EGFR TKI

Single dose of AAVrh.10anti-IgE blocks peanut-induced anaphylaxis

Non-small cell lung cancer candidate PF-06463922 receives orphan drug status from FDA

Invega Trinza launched in the U.S.

Alexion completes acquisition of Synageva BioPharma

European Commission approves Lixiana

Vertex Pharmaceuticals discloses ATR kinase inhibitors

Recent Merck & Co. patent describes FFAR1 agonists

Victoria Link prepares and tests analogues of TAN-2483A

Chemokine CCR6 receptor antagonists reported in ChemoCentryx patent

GnRH receptor antagonists patented by Bayer

Velcade Injection 3 mg approved in additional indication in Japan

Aquinox Pharmaceuticals reports data from LEADERSHIP trial

Cabaletta receives European orphan drug status for oculopharyngeal muscular dystrophy

Advanced Accelerator Applications completes new financing

FDA clears IND for first-in-human study of Aurora B kinase inhibitor AZD-2811

MM-398 accepted for review in E.U., granted priority review by FDA

Basilea initiates phase I/IIa study of oral BAL-101553 in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.